Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis
NCT02821689
·
clinicaltrials.gov ↗
PHASE4
Phase
UNKNOWN
Status
57
Enrollment
OTHER
Sponsor class
Conditions
Dermatopolymyositis
Interstitial Lung Disease
Interventions
DRUG:
Pirfenidone
Sponsor
RenJi Hospital